InMed Pharmaceuticals
11 hedge funds and large institutions have $117K invested in InMed Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 8 closing their positions.
6.05% less ownership
Funds ownership: 11.32% → 5.27% (-6.1%)
27% less funds holding
Funds holding: 15 → 11 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
73% less capital inflows, than outflows
Capital inflows: $34.5K | Capital outflows: $129K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Virtu Financial
New York
|
+$24.8K |
| 2 |
XTX Topco
George Town,
Cayman Islands
|
+$5.09K |
| 3 |
HRT Financial
New York
|
+$4.57K |
| 4 |
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
+$23 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$97.2K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$15.6K |
| 3 |
Renaissance Technologies
New York
|
-$10K |
| 4 |
Two Sigma Securities
New York
|
-$5.61K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$177 |
INM Hedge Fund Activity: Q2 2024 in Review
11 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q2 2024, worth a combined $117K — down 53% from $249K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of INM and 4 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $24.8K. The largest seller was Armistice Capital, exiting entirely with an estimated $97.2K sold.
- 11 institutional investors held InMed Pharmaceuticals (INM) as of Q2 2024, down from 15 in Q1 2024.
- Funds reported $117K of InMed Pharmaceuticals stock for Q2 2024, down 53% quarter-over-quarter.
- 4 funds opened new InMed Pharmaceuticals positions in Q2 2024 and 8 closed out, a net change of -4 holders.
- The largest InMed Pharmaceuticals buyer in Q2 2024 was Virtu Financial, an estimated $24.8K added.
- The largest InMed Pharmaceuticals seller in Q2 2024 was Armistice Capital, an estimated $97.2K sold.
Based on aggregated 13F filings for Q2 2024.